Scholar Rock (NASDAQ:SRRK – Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
Scholar Rock Stock Performance
Shares of SRRK stock opened at $34.60 on Monday. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock has a 12-month low of $6.76 and a 12-month high of $46.98. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -14.72 and a beta of 0.59. The stock has a 50 day simple moving average of $39.46 and a 200-day simple moving average of $31.50.
Insider Buying and Selling
In related news, insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the sale, the insider now owns 111,084 shares of the company’s stock, valued at $4,154,541.60. The trade was a 38.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jing L. Marantz sold 5,655 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the sale, the insider now directly owns 67,200 shares of the company’s stock, valued at $2,970,240. The trade was a 7.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 292,266 shares of company stock valued at $10,996,151 in the last quarter. Company insiders own 19.20% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Research Report on Scholar Rock
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Articles
- Five stocks we like better than Scholar Rock
- How to Invest in Insurance Companies: A GuideĀ
- How to Build the Ultimate Everything ETF Portfolio
- Options Trading – Understanding Strike Price
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.